Previous 10 | Next 10 |
Recent news releases related news releases and press releases from 11/07/23 07:00:59 on US and Canada Markets.
LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday, November 14, 2023, before market open. The Company will host a corresponding conference call and liv...
Advancing dose escalation portion of Phase 1 clinical trial of XMT-1660, Mersana’s B7-H4 Dolasynthen ADC Preparations underway to resume enrollment in Phase 1 clinical trial of XMT-2056, Mersana’s HER2 Immunosynthen ADC Capital resources expected to support current o...
– Enrollment continues in the 2L Phase 3 VERITAC-2 trial and study lead-in for the VERITAC-3 1L Phase 3 trial with vepdegestrant; Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Bavdegalutamide mCRPC data presented at ESMO showed median rPFS of ...
Sales of $949 million, up 13% 17% organic sales growth in infrastructure-related businesses EBITDA (1) of $193 million, or a margin (1) of 20.3%, up from 14.1% in Q3 2022 Net income of $110 million, or $1.91 per share, up 79% from EPS in Q3 2022 ...
EAGAN, Minn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) ...
-- Third quarter 2023 net revenue from global sales of IMCIVREE ® (setmelanotide) of $22.5 million -- -- More than 100 international patients on reimbursed IMCIVREE therapy -- -- Phase 3 hypothalamic obesity trial on track to be fully enrolled by the end of 2023 -...
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced today that it has achieved its third pre-specified resear...
Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Pemvidutide granted Fast Track designation for the treatment of non-alcoholic steatohepatitis (NASH) Top-line results from the Phase 2 trial of HepTcell™ in chronic hepatitis B (CHB) expecte...
New Clinical Data from MD Anderson Presented at the Society for Immunotherapy of Cancer’s 38 th Annual Meeting 80% DCR (disease control rate) in non-radiated tumor with Durable Responses in Heavily Pretreated Patients in 6 different cancers Full data was...
HAMILTON LANE INCORPORATED REPORTS SECOND QUARTER FISCAL 2024 RESULTS, WITH MANAGEMENT & ADVISORY FEES GROWING BY 18% AND ASSETS UNDER MANAGEMENT GROWING BY 11% YEAR-OVER-YEAR HAMILTON LANE INCORPORATED REPORTS SECOND QUARTER FISCAL 2024 RESULTS, WITH MANAGEMENT & ADVISORY FEES ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
20.92%Change Percent:
Snap Inc. Class A Company Name:
SNAP Stock Symbol:
NYSE Market:
snap.com Website: